Dishman Carbogen Amcis Limited announced its un-audited financial results for the third quarter ended December 31, 2025, during a board meeting held on February 3, 2026. The company reported a consolidated total income of Rs. 726.46 Crores for the quarter, reflecting a growth in operations compared to both the previous quarter and the corresponding quarter of the previous year. However, the company faced a net loss of Rs. 12.97 Crores for the period, a significant decline from the profits recorded in earlier quarters. This performance was impacted by increased employee benefit expenses and higher depreciation costs.

Dishman Carbogen Amcis Limited is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of drug development and commercialization services. The company operates as a Contract Development and Manufacturing Organization (CDMO), providing integrated solutions including process development, analytical services, and the manufacture of Active Pharmaceutical Ingredients (APIs). In recent 2025 updates, the company successfully completed major regulatory audits at its facilities, which is expected to improve its India business performance. The robust outlook in the CDMO sector continues to support its growth path, despite the recent quarterly loss. Notable investors in the company have historically included various institutional funds, though specific major movements in 2025 focus on the board’s strategic decisions regarding goodwill reassessment to reflect fair value.